1. Pink Sheet
  2. >>R&D

Historic Output Of Disease-Specific Guidances Is Among Gottlieb's Legacies At US FDA

 
• By Michael Cipriano

A Pink Sheet analysis illustrates how the outgoing commissioner enhanced FDA's ability to facilitate the further development of innovative drugs. 

At the beginning of his tenure, now-outgoing US FDA Commissioner Scott Gottlieb said the agency will be prioritizing the development of disease-specific guidance documents as a way to facilitate innovative drug development. (Also see "FDA's Gottlieb Pushing 'Seamless' Clinical Trials For Faster Development" - Pink Sheet, 12 September, 2017.) He certainly looks to have kept that promise.

A Pink Sheet analysis of FDA guidance documents shows that FDA issued 36 disease-specific guidances during Gottlieb's nearly 22 months...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Pink Sheet

New EFPIA President Hopes ‘Sanity Will Prevail’ In EU Pharma Reform Dialogs

 
• By Eliza Slawther

Stefan Oelrich, the newly-announced president of European pharma industry federation EFPIA says the EU pharma reform is “not an improvement on the status quo” in its current form.

UK Pilots Faster Setup Of Early Phase Oncology Trials

 
• By Vibha Sharma

Oncology trial sponsors in the UK are being invited to participate in a pilot that aims to tackle duplication and variation in pharmacy reviews, which are an important part of setting up clinical trials in the National Health Service.

US CDC Vaccine Committee Revives Thimerosal Debate: A Portent Of Things To Come?

 
• By Bridget Silverman

The new Advisory Committee on Immunization Practices voted for new recommendations on the decades-old thimerosal safety issue and lays intellectual groundwork to revisit other past controversies and decisions.